Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluatie van lasofoxifen in combinatie met abemaciclib in vergelijking met fulvestrant in combinatie met abemaciclib bij lokaal gevorderde of gemetastaseerde ER+/HER2-borstkanker met een ESR1-mutatie (ELAINEIII)

10 november 2026 bijgewerkt door: LeonaBio

Een open-label, gerandomiseerd, multicenter onderzoek waarin de werkzaamheid en veiligheid van de combinatie van lasofoxifen en abemaciclib wordt vergeleken met de combinatie van fulvestrant en abemaciclib voor de behandeling van pre- en postmenopauzale vrouwen en mannen met lokaal gevorderde of gemetastaseerde ER+/HER2-borstkanker met een ESR1-mutatie

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.

The main question the study aims to answer is:

• To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

600

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Simon Daggett - Senior Vice President, Clinical Operations
  • Telefoonnummer: (425) 620-8772 (909) 374-3793
  • E-mail: clinicaltrials@leonabio.com

Studie Locaties

    • Ontario
      • Ottawa, Ontario, Canada
        • Werving
        • The Ottawa General Hospital
        • Contact:
      • Toronto, Ontario, Canada
        • Werving
        • Sunnybrook Health Sciences Centre -Bayview Campus
        • Contact:
    • Quebec
      • Montreal, Quebec, Canada
      • Montreal, Quebec, Canada
      • Saguenay, Quebec, Canada
        • Ingetrokken
        • CIUSSS du Saguenay-Lac-Saint-Jean
      • Anhui, China
        • Werving
        • Anhui Provincial Cancer Hospital
        • Contact:
      • Anyang, China
      • Beijing, China
        • Werving
        • Peking Union Medical College Hospital
        • Contact:
      • Beijing, China
      • Bengbu, China
        • Werving
        • The First Affiliated Hospital of Bengbu Medical University
        • Contact:
      • Changchun, China
        • Werving
        • The First Hospital of Jilin University
        • Contact:
      • Changsha, China
        • Werving
        • The Second Xiangya Hospital of Central South University
        • Contact:
      • Chengdu, China
        • Werving
        • Sichuan Provincial People's Hospital
        • Contact:
      • Chengdu, China
        • Werving
        • West China Hospital, Sichuan University
        • Contact:
      • Chongqicun, China
        • Werving
        • The First Affiliated Hospital, Chongqing Medical University
        • Contact:
      • Dalian, China
        • Werving
        • The Second Hospital of Dalian Medical University
        • Contact:
      • Deyang, China
        • Werving
        • Deyang People's Hospital
        • Contact:
      • Fuyang, China
        • Werving
        • Fuyang Cancer Hosptial
        • Contact:
      • Fuzhou, China
        • Werving
        • Fujian Cancer Hospital
        • Contact:
      • Fuzhou, China
        • Werving
        • Fujian Medical University Union Hospital
        • Contact:
      • Guandong, China
        • Werving
        • Zhujiang Hospital of Nanfang Medical University
        • Contact:
      • Guangdong, China
        • Werving
        • Guangdong Provincial People's Hospital
        • Contact:
      • Guangdong, China
        • Werving
        • Meizhou People's Hospital
        • Contact:
      • Guangdong, China
        • Werving
        • Peking University Shenzhen Hospital
        • Contact:
          • Xiaoling Liu
      • Guangdong, China
        • Werving
        • Sun Yat-Sen University- Cancer Center
        • Contact:
      • Guangzhou, China
        • Werving
        • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
        • Contact:
      • Haikou, China
        • Werving
        • The First Affiliated Hospital of Hainan Medical University
        • Contact:
      • Hangzhou, China
        • Werving
        • The First Affiliated Hospital, College of Medicine, Zhejiang University
        • Contact:
      • Hangzhou, China
        • Werving
        • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
        • Contact:
      • Hangzhou, China
        • Werving
        • Zhejiang Provincial Hospital of Chinese Medicine
        • Contact:
      • Hebei, China
        • Werving
        • Hebei Medical University - The Fourth Hospital - Hebei Provincial Tumor Hospital
        • Contact:
      • Hubei, China
        • Werving
        • Xiangyang Central Hospital
        • Contact:
      • Hunan, China
        • Werving
        • Xiangya Hospital Central South University
        • Contact:
      • Jieyang, China
        • Werving
        • Jieyang People's Hospital
        • Contact:
      • Jinan, China
        • Werving
        • Shandong Province Tumor Hospital
        • Contact:
      • Kunming, China
      • Lanzhou, China
        • Werving
        • The First Hospital of Lanzhou University
        • Contact:
      • Lanzhou, China
        • Werving
        • Gansu Provincial Hospital
        • Contact:
      • Linyi, China
        • Werving
        • Linyi Cancer Hospital
        • Contact:
      • Luoyang, China
        • Werving
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Contact:
      • Luoyang, China
        • Werving
        • Luoyang Central Hospital
        • Contact:
      • Luzhou, China
        • Werving
        • The Affiliated Hospital of Southwest Medical University (Luzhou Medical College)
        • Contact:
      • Nanchang, China
        • Werving
        • Jiangxi Cancer Hospital
        • Contact:
      • Nanchang, China
        • Werving
        • Nanchang People's Hospital
        • Contact:
      • Nanjing, China
        • Werving
        • Nanjing Drum Tower Hospital
        • Contact:
      • Nanjing, China
        • Werving
        • Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University
        • Contact:
      • Nanning, China
        • Werving
        • Guangxi Medical University Cancer Hospital
        • Contact:
      • Nanyang, China
        • Werving
        • Nanyang Central Hospital
        • Contact:
      • Neijiang, China
        • Werving
        • The Second People's Hospital of Neijiang
        • Contact:
      • Ningbo, China
        • Werving
        • Ningbo Medical Center Li Huili Hospital
        • Contact:
      • Pingdingshan, China
        • Werving
        • The First People'S Hospital of Ping Ding Shan
        • Contact:
      • Qingdao, China
        • Werving
        • The Affiliated Hospital of Qingdao University
        • Contact:
      • Qingdao, China
        • Werving
        • Qingdao Central Hospital, University of Health and Rehabilitation Sciences
        • Contact:
      • Quanzhou, China
        • Werving
        • Quanzhou First Hospital
        • Contact:
      • Shanghai, China
        • Werving
        • Huashan Hospital, Fudan University
        • Contact:
      • Shanghai, China
        • Werving
        • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
        • Contact:
      • Shang’ai, China
        • Werving
        • Fudan University Cancer Center
        • Contact:
      • Shanxi, China
        • Werving
        • First Affiliated Hospital of Xi'an Jiaotong University
        • Contact:
      • Shaoyang, China
        • Werving
        • The Central Hospital of Shaoyang
        • Contact:
      • Shenyang, China
        • Werving
        • Liaoning Cancer Hospital & Institute
        • Contact:
      • Shouguang, China
        • Werving
        • Yuebei People's Hospital
        • Contact:
      • Sichuan, China
        • Werving
        • University of Electonic Science & Technology (UESTC) - Sichuan Cancer Hospital & Institute
        • Contact:
      • Tianjin, China
        • Werving
        • Tianjin Medical University Cancer Institute & Hospital
        • Contact:
      • Tianjin, China
        • Werving
        • Tianjin Cancer Hospital Airport Hospital
        • Contact:
      • Wenzhou, China
        • Werving
        • The First Affiliated Hospital of Wenzhou Medical University
        • Contact:
      • Wuhan, China
        • Werving
        • Hubei Cancer Hospital
        • Contact:
      • Wuhan, China
        • Werving
        • Union Hospital Tongji Medical College Huazhong University of Science and Technolog
        • Contact:
      • Wuhu, China
        • Werving
        • The Second People's Hospital of WuHu
        • Contact:
      • Xi Ail, China
        • Werving
        • The First Affiliated Hospital of Air Force Medical University
        • Contact:
      • Xiamen, China
        • Werving
        • Zhongshang Hospital Xiamen University
        • Contact:
      • Xiamen, China
        • Werving
        • The first affiliated hospital of Xiamen University
        • Contact:
      • Xinzheng, China
        • Werving
        • The Second Affiliated Hospital Of Xi'an Jiaotong University
        • Contact:
      • Xuzhou, China
        • Werving
        • The Affiliated Hospital of Xuzhou Medical University
        • Contact:
      • Xuzhou, China
        • Werving
        • Xuzhou Central Hospital
        • Contact:
      • Yuncheng, China
        • Werving
        • Yuncheng Central Hospital
        • Contact:
      • Zhejiang, China
        • Werving
        • Zhejiang Provincial People's Hospital
        • Contact:
      • Zhejiang, China
        • Werving
        • Zhejiang cancer hospital
        • Contact:
      • Zhengzhou, China
        • Werving
        • Henan Cancer Hospital
        • Contact:
      • Zhengzhou, China
        • Werving
        • The First Affiliated Hospital of Zhengzhou University
        • Contact:
      • Zhongshan, China
        • Werving
        • Zhongshan City People's Hospital
        • Contact:
      • Zhumadian, China
        • Werving
        • Zhumadian Central Hospital
        • Contact:
      • Ürümqi, China
        • Werving
        • The Affiliated Cancer Hospital of Xinjiang Medical University
        • Contact:
      • Dresden, Duitsland
      • München, Duitsland
        • Werving
        • Klinikum rechts der Isar der Technischen Universitaet Muenchen
        • Contact:
      • Afula, Israël, 1834111
      • Beersheba, Israël, 8486614
      • Haifa, Israël
      • Jerusalem, Israël
      • Jerusalem, Israël
        • Werving
        • Hadassah Ein-Karem Medical Center
        • Contact:
      • Kfar Saba, Israël, 4428164
      • Petah Tikva, Israël
      • Rehovot, Israël
        • Werving
        • Kaplan Medical Center
        • Contact:
      • Tel Aviv, Israël
      • Tel HaShomer, Israël
      • Ancona, Italië
      • Aviano, Italië
      • Candiolo, Italië, 10060
      • Meldola, Italië
        • Werving
        • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.
        • Contact:
      • Milan, Italië
      • Misterbianco, Italië
      • Modena, Italië
        • Werving
        • Azienda Ospedaliero-Universitaria di Modena
        • Contact:
      • Naples, Italië
      • Novara, Italië, 28100
        • Ingetrokken
        • Azienda Ospedaliero Universitaria Maggiore Della Carita
      • Padova, Italië, 35128
      • Parma, Italië
      • Pavia, Italië
        • Werving
        • Fondazione IRCCS Policlinico San Matteo
        • Hoofdonderzoeker:
          • Gianpiero Rizzo
        • Contact:
      • Roma, Italië
      • Verona, Italië
        • Voltooid
        • Azienda Ospedaliera Universitaria Integrata Verona-Ospedale Borgo Trento
      • Biała Podlaska, Polen
        • Ingetrokken
        • KO - MED Centra Kliniczne Sp. z o.o., Wojewodzki Szpital Specjalistyczny w Bialej Podlaskiej
      • Gliwice, Polen
        • Ingetrokken
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Oddzial w Gliwicach, I Klinika Radioterapii i Chemioterapii
      • Krakow, Polen
        • Werving
        • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie - Oddzial Onkologii Klinicznej z Pododdzialem Dziennym
        • Contact:
      • Krakow, Polen
      • Lodz, Polen
        • Voltooid
        • Instytut Centrum Zdrowia Matki Polki - Klinika Onkologii
      • Poznan, Polen
        • Werving
        • Uniwersytecki Szpital Kliniczny w Poznaniu, Oddzial Chemioterapii
        • Contact:
      • Poznan, Polen
        • Werving
        • Wielkopolskie Centrum Onkologii (WCO) / The Greater Poland Cancer Center
        • Contact:
      • Wieliszew, Polen
      • Bucharest, Roemenië
        • Werving
        • Memorial Healthcare International SRL
        • Contact:
      • Bucharest, Roemenië
        • Ingetrokken
        • Centrul Medical Focus
      • Cluj-Napoca, Roemenië
      • Craiova, Roemenië
        • Werving
        • Oncology Center Sfantul Nectarie
        • Contact:
      • Craiova, Roemenië
        • Voltooid
        • Onco Clinic Consult SA
      • Piteşti, Roemenië
      • Timișoara, Roemenië
        • Werving
        • OncoMed Oncology Center
        • Contact:
      • Barcelona, Spanje
        • Werving
        • Hospital Universitario Vall d'Hebron
        • Contact:
          • Miriam Arumi de Dios
          • Telefoonnummer: +34600240679
          • E-mail: marumi@vhio.net
      • Barcelona, Spanje
      • Córdoba, Spanje
        • Werving
        • Hospital Universitario Reina Sofia
        • Contact:
      • Madrid, Spanje, 28034
        • Werving
        • Hospital Universitario Ramon y Cajal
        • Contact:
      • Madrid, Spanje, 28040
      • Madrid, Spanje
        • Werving
        • Hospital Universitario 12 de Octubre
        • Contact:
      • Madrid, Spanje
      • Madrid, Spanje
        • Werving
        • Clinica Universidad de Navarra - Madrid
        • Contact:
      • Madrid, Spanje
        • Werving
        • Hospital Beata Maria Ana
        • Contact:
      • Madrid, Spanje
        • Werving
        • Hospital General Universitario Gregorio Maranon
        • Contact:
      • Málaga, Spanje
      • Pamplona, Spanje
        • Werving
        • Clinica Universidad de Navarra - Pamplona
        • Contact:
      • Valencia, Spanje
        • Werving
        • Instituto Valenciano de Oncologia
        • Contact:
      • Changhua, Taiwan
        • Werving
        • Changhua Christian Hospital (CCH)
        • Contact:
      • Kaohsiung City, Taiwan
        • Werving
        • Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
        • Contact:
      • Tainan, Taiwan
        • Werving
        • National Cheng Kung University Hospital
        • Contact:
      • Taipei, Taiwan
        • Werving
        • National Taiwan University Hospital
        • Contact:
      • Taipei, Taiwan
        • Werving
        • Tri-Service General Hospital
        • Contact:
      • Taipei, Taiwan
        • Werving
        • Koo Foundation Sun Yat-Sen Cancer Center
        • Contact:
      • Taoyuan City, Taiwan
      • Ankara, Turkije (Türkiye)
        • Werving
        • Ankara University Medical Faculty Medical Oncology Department
        • Contact:
      • Bursa, Turkije (Türkiye)
        • Werving
        • Uludag University Faculty of Medicine Hospital
        • Contact:
      • Edirne, Turkije (Türkiye)
      • Izmir, Turkije (Türkiye)
    • Ankara
      • Çankaya, Ankara, Turkije (Türkiye)
    • Istanbul
      • Kadiköy, Istanbul, Turkije (Türkiye)
        • Werving
        • Goztepe Prof. Dr. Suleyman Yalcin City Hospital
        • Contact:
      • Çapa, Istanbul, Turkije (Türkiye)
    • Kocaeli
    • İzmir
      • Bornova, İzmir, Turkije (Türkiye)
      • Konak, İzmir, Turkije (Türkiye)
      • Cardiff, Verenigd Koninkrijk, CF14 2TL
      • Harlow, Verenigd Koninkrijk, CM20 1QX
        • Werving
        • Princess Alexandra Hospital - Harlow
        • Contact:
      • Leeds, Verenigd Koninkrijk
      • London, Verenigd Koninkrijk
      • London, Verenigd Koninkrijk, NW3 2
        • Werving
        • Royal Free London NHS Foundation Trust
        • Contact:
      • Manchester, Verenigd Koninkrijk
      • Milton Keynes, Verenigd Koninkrijk, MK6 5LD
      • Nottingham, Verenigd Koninkrijk
      • Stockton-on-Tees, Verenigd Koninkrijk, TS198PE
        • Ingetrokken
        • University Hospital of North Tees
    • Arizona
      • Scottsdale, Arizona, Verenigde Staten, 85259
        • Werving
        • Mayo Clinic - Scottsdale
        • Contact:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefoonnummer: 855-776-0015
      • Tucson, Arizona, Verenigde Staten, 85719
        • Werving
        • University of Arizona - Cancer Center
        • Contact:
    • California
      • Santa Rosa, California, Verenigde Staten, 95403
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32224
        • Werving
        • Mayo Clinic - Jacksonville
        • Contact:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefoonnummer: 855-776-0015
      • Miami, Florida, Verenigde Staten, 33143
      • Plantation, Florida, Verenigde Staten, 33324
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
    • Kentucky
    • Maryland
      • Baltimore, Maryland, Verenigde Staten, 21231
        • Werving
        • Johns Hopkins Kimmel Cancer Center
        • Contact:
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Voltooid
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Verenigde Staten, 02115
    • Michigan
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Werving
        • Cancer and Hematology Centers of Western Michigan
        • Contact:
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Voltooid
        • Allina Health System DBA Virginia Piper Cancer Institute
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Werving
        • Mayo Clinic - Rochester
        • Contact:
          • Clinical Trials Office - All Mayo Clinic Locations
          • Telefoonnummer: 855-776-0015
    • Missouri
      • Kansas City, Missouri, Verenigde Staten, 64111
        • Werving
        • Saint Luke's Cancer Institute
        • Contact:
      • St Louis, Missouri, Verenigde Staten, 63110
        • Werving
        • Washington University School of Medicine
        • Contact:
    • Nevada
      • Reno, Nevada, Verenigde Staten, 89502
      • Reno, Nevada, Verenigde Staten, 89511-2250
    • New Jersey
      • Belleville, New Jersey, Verenigde Staten, 07109
        • Ingetrokken
        • New Jersey Cancer Care, PA
      • New Brunswick, New Jersey, Verenigde Staten, 08901
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 87110
        • Nog niet aan het werven
        • Presbyterian Kaseman Hospital
        • Contact:
      • Rio Rancho, New Mexico, Verenigde Staten, 87124
        • Werving
        • Presbyterian Rust Cancer Center
        • Contact:
    • New York
      • New York, New York, Verenigde Staten, 10029
      • New York, New York, Verenigde Staten, 10065
        • Werving
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
        • Contact:
      • New York, New York, Verenigde Staten, 10011
        • Werving
        • The Blavatnik Family - Chelsea Medical Center at Mount Sinai
        • Contact:
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27705
        • Werving
        • Duke University Medical Center
        • Contact:
    • North Dakota
      • Grand Forks, North Dakota, Verenigde Staten, 58201
        • Voltooid
        • Altru Health Systems
    • Ohio
      • Cleveland, Ohio, Verenigde Staten, 44106
      • Cleveland, Ohio, Verenigde Staten, 44119
        • Ingetrokken
        • Cleveland Clinic
      • Columbus, Ohio, Verenigde Staten, 42112
        • Werving
        • The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James)
        • Contact:
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15232
        • Voltooid
        • University of Pittsburgh Medical Center
    • Texas
      • Houston, Texas, Verenigde Staten, 77030
      • Houston, Texas, Verenigde Staten, 77030
      • Houston, Texas, Verenigde Staten, 77054
        • Werving
        • Harris Health System - Smith Clinic
        • Hoofdonderzoeker:
          • Ahmed Elkhanany
        • Contact:
    • Washington
      • Seattle, Washington, Verenigde Staten, 98104
        • Ingetrokken
        • Swedish Cancer Institute (SCI)
      • Gyeonggi-do, Zuid -Korea
        • Werving
        • National Cancer Center
        • Contact:
      • Jeollanam-do, Zuid -Korea, 58128
        • Werving
        • Chonnam National University Hwasun Hospital
        • Contact:
      • Seoul, Zuid -Korea
        • Werving
        • Korea University Anam Hospital
        • Contact:
      • Seoul, Zuid -Korea
        • Ingetrokken
        • Severance Hospital, Yonsei University Health System
      • Seoul, Zuid -Korea
        • Ingetrokken
        • Asan Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Pre- or postmenopausal women or men.

  2. Locally advanced and/or metastatic ER+ breast cancer with radiological or clinical evidence of progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease.

  3. Histological or cytological confirmation of ER+/HER2 - disease

  4. No evidence of progression for at least 6 months on an AI/CDKi combination for advanced breast cancer.

  5. At least 1 or more ESR1 point mutations in the ESR1 ligand binding domain as assessed in cell- free ctDNA obtained from a blood or breast cancer tissue.

  6. Locally advanced or metastatic breast cancer with at least 1 measurable (according to RECIST 1.1) lesion with or without non-measurable lesions.

  7. Subjects may have received 1 cytotoxic chemotherapy regimen in the metastatic disease setting prior to study entry, but must have recovered from chemotherapy acute toxicity excluding alopecia and Grade 2 peripheral neuropathy.

  8. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

  9. Adequate organ function

  10. Able to swallow tablets

  11. Brain metastases are allowed only if the following 4 parameters hold:

    1. Asymptomatic,
    2. Definitively treated (e.g., radiotherapy, surgery),
    3. Not requiring steroids up to 4 weeks before study treatment initiation, AND
    4. Central nervous system disease stable for >3 months prior to registration as documented by magnetic resonance imagining (MRI).
  12. Able to understand and voluntarily sign a written informed consent before any screening procedures.

  13. Every attempt should be made to obtain a biopsy of metastatic breast cancer tissue, when safe and feasible, to provide histological or cytological confirmation of ER+/HER2- disease as assessed by a local laboratory, according to American Society of Clinical Oncology/College of American Pathologists guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is done, it may undergo genomic testing at some point to assess for ESR1 mutations and correlation with ctDNA results. If a biopsy is not possible or inappropriate from a clinical standpoint, the ER and HER2 status from the subject's most recent biopsy must confirm that the subject is ER+ and HER2

Exclusion Criteria:

  1. Lymphangitic carcinomatosis involving the lung.
  2. History of Grade 3 or Grade 4 interstitial lung disease (ILD) on previous therapy.
  3. Visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  4. Prior progression of disease on abemaciclib, fulvestrant, or other selective estrogen receptor degrader (SERD) therapy.
  5. Subjects with a known hypersensitivity to fulvestrant or to any of the excipients
  6. Radiotherapy within 30 days prior to Visit 0 (Day 1) except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to Visit 0 (Day 1). Subjects must have recovered from radiotherapy toxicities prior to Visit 0 (Day 1).
  7. Known RB1 mutations or deletions that in the opinion of the investigator confer resistance to CDK4/6i. (Screening for RB1 mutation is not required for entry.)
  8. History of long QTc (Q-T interval corrected for heart rate) syndrome or a QTc of >480 msec.
  9. History of a pulmonary embolus (PE), deep vein thrombosis (DVT), or any known thrombophilia, unless the event occurred greater than 6 months prior to screening and the subject is treated with chronic anticoagulant therapy such as apixaban (Eliquis) or rivaroxaban (Xarelto).
  10. Lasofoxifene is not recommended for use in subjects with conditions that place them at increased risk for VTEs (such as severe congestive heart failure [CHF] or prolonged immobilization).
  11. On concomitant strong CYP3A4 inhibitors.
  12. On strong and moderate CYP3A4 inducers.
  13. Any significant co-morbidity that would impact the study or the subject's safety, including subjects with significant malabsorption.
  14. Active systemic bacterial or fungal infection (requiring intravenous [IV] antibiotics or antifungals at the time of initiating study treatment).
  15. Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
  16. History of malignancy within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery.
  17. Positive serum pregnancy test (only if premenopausal).
  18. Sexually active premenopausal women and men unwilling to use double-barrier contraception.
  19. Women who are breast feeding
  20. History of non-compliance to medical regimens.
  21. Unwilling or unable to comply with the protocol.
  22. Current participation in any clinical research trial involving an investigational drug or device within the last 30 days.
  23. Subjects with a history of familial hypertriglyceridemia or fasting triglyceride levels >880 mg/dL at screening.
  24. Fasting triglyceride level >300 mg/dL and ≤880 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting triglyceride level less than or equal to 300 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).
  25. Fasting cholesterol level >400 mg/dL at screening. Subjects may be retested and enrolled if they have a repeat fasting cholesterol level less than or equal to 400 mg/dL prior to enrollment (e.g., after adjustment with diet and/or treatment).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treatment

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day

Actieve vergelijker: Reference Therapy

Pre- and Postmenopausal Women and Men with locally advanced or metastatic ER+/HER2- breast cancer who have disease progression on an AI in combination with either palbociclib or ribociclib as their first hormonal treatment for metastatic disease and who have an ESR1 mutation.

Fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression free survival (PFS)
Tijdsspanne: Within approximately 3 years

PFS is defined as the time from the date of randomization [Visit 0 (Day 1)] to the earliest date of first documented progression per RECIST 1.1 as determined by BICR or death due to any cause.

Within approximately 3 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Objective response rate (ORR)
Tijdsspanne: Within approximately 3 years

ORR is defined as the percentage of subjects with measurable disease at baseline whose best overall response is either a confirmed CR or a confirmed PR according to RECIST 1.1.

Within approximately 3 years
Overall survival (OS)
Tijdsspanne: Within approximately 3 years

Overall survival is defined as time from the date of Visit 0 (Day 1) to death due to any cause.

Within approximately 3 years
Clinical benefit rate (CBR)
Tijdsspanne: Within approximately 3 years

CBR is defined as the percentage of subjects with best overall response of confirmed CR, confirmed PR, or stable disease (SD) with a duration of 24 weeks or longer according to RECIST 1.1. As used in this calculation, stable disease is defined as stable disease in those subjects with measurable disease plus nonPR/non progressive disease (PD) in subjects with non-measurable disease.

Within approximately 3 years
Duration of response (DoR) in subjects with an objective response
Tijdsspanne: Within approximately 3 years

DoR is from the date of first documented confirmed response (CR or PR) to the date of first documented progression of disease or death due to any cause, whichever is earlier.

Within approximately 3 years
Time to response (TTR) in subjects with an objective response
Tijdsspanne: Within approximately 3 years

TTR is from the date of randomization to the date of first documented confirmed response (CR or PR).

Within approximately 3 years
Time to cytotoxic chemotherapy
Tijdsspanne: Within approximately 3 years

From the date of randomization to the date of first documented use of cytotoxic chemotherapy.

Within approximately 3 years
Quality of Life (QoL) evaluated using the Functional Assessment of Cancer Therapy-Breast Cancer-Endocrine Subscale (FACT B-ES)
Tijdsspanne: Within approximately 3 years

Scale ranges from 'Not at all' to 'Very much'

Within approximately 3 years
Incidence of Adverse Events (AEs) and Serious AEs
Tijdsspanne: Within approximately 3 years

The type, severity (graded by Common Terminology Criteria for Adverse Events [CTCAE version 5.0]), course, duration, seriousness, and relationship to study treatment will be assessed at each visit

Within approximately 3 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

31 oktober 2023

Primaire voltooiing (Geschat)

1 april 2027

Studie voltooiing (Geschat)

1 april 2028

Studieregistratiedata

Eerst ingediend

13 januari 2023

Eerst ingediend dat voldeed aan de QC-criteria

13 januari 2023

Eerst geplaatst (Werkelijk)

25 januari 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

13 november 2026

Laatste update ingediend die voldeed aan QC-criteria

10 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren